KCAT	Homo sapiens	0.3	RAARVVGG	*
KCAT	Homo sapiens	0.3	RLARVVGG	*
KCAT	Homo sapiens	0.3	RQARAVGG	*
KCAT	Homo sapiens	0.3	RRARVVGG	*
KCAT	Homo sapiens	0.5	RQLRVVGG	*
KCAT	Rattus norvegicus	0.57	single-chain urokinase-type plasminogen activator	*catalytic domain, Asp603 - Val855, after treatment with enteropeptidase
KCAT	Homo sapiens	0.6	RYARVVGG	*
KCAT	Homo sapiens	0.7	RQYRVVGG	*
KCAT	Rattus norvegicus	0.71	single-chain urokinase-type plasminogen activator	*extracellular domains, Tyr81 - Val855, after treatment with enteropeptidase
KCAT	Homo sapiens	0.8	RQARQVGG	*
KCAT	Homo sapiens	0.89	pro-urokinase plasminogen activator	*
KCAT	Homo sapiens	0.9	RRARVVGG	*
KCAT	Homo sapiens	1	matriptase	*
KCAT	Homo sapiens	1	RQARVVGG	*
KCAT	Homo sapiens	1.5	matriptase	*
KCAT	Rattus norvegicus	1.5	methylsulfonyl-D-cyclohexyltyrosylglycyl-arginine-p-nitroanilide	*construct consisting of the catalytic domain of matriptase bearing a N772Q mutation fused to Myc-epitope-hexahistidine tag at its carboxyl-terminus treated with recombinant enterokinase
KCAT	Homo sapiens	1.5	RQARVVGG	*
KCAT	Homo sapiens	2	RQARYVGG	*
KCAT	Homo sapiens	2.2	protease-activated receptor-2	*
KCAT	Homo sapiens	2.24	ABZ-Ile-Arg-Ala-Arg-Ser-Ala-Ala-Tyr(3-NO2)-NH2	*pH and temperature not specified in the publication
KCAT	Homo sapiens	2.66	ABZ-Ile-Arg-Ala-Arg-Ser-Ala-Ser-Tyr(3-NO2)-NH2	*pH and temperature not specified in the publication
KCAT	Homo sapiens	3.79	ABZ-Ile-Arg-Ala-Arg-Ser-Ala-Gly-Tyr(3-NO2)-NH2	*pH and temperature not specified in the publication
KCAT	Homo sapiens	5.5	RQARAVGG	*
KCAT	Homo sapiens	6.8	filaggrin	*
KCAT	Homo sapiens	7.2	alphaEbeta7 i tegrin	*
KCAT	Homo sapiens	7.2	trask	*
KCAT	Rattus norvegicus	13.1	t-butyloxycarbonyl-L-Gln-L-Ala-L-Arg-4-methyl-coumaryl-7-amide	*extracellular domains, Tyr81 - Val855, after treatment with enteropeptidase
KCAT	Rattus norvegicus	13.7	t-butyloxycarbonyl-L-Gln-L-Ala-L-Arg-4-methyl-coumaryl-7-amide	*catalytic domain, Asp603 - Val855, after treatment with enteropeptidase
KCAT	Homo sapiens	26	RQRRVVGG	*
KCAT	Homo sapiens	32	filaggrin	*
KCAT	Homo sapiens	45	alphaEbeta7 i tegrin	*
KCAT	Homo sapiens	46	trask	*
KCAT	Rattus norvegicus	59	methylsulfonyl-D-cyclohexyltyrosylglycyl-arginine-p-nitroanilide	*full-length rat matriptase with Myc-epitope-hexahistidine tag at its carboxyl-terminus
KCAT	Rattus norvegicus	59	methylsulfonyl-D-cyclohexyltyrosyl-glycyl-arginine-p-nitroanilide	*engineered L-matriptase (secreted variant of matriptase activated by recombinant enterokinase); pseudozymogen His6t-S-CD consisting of a spacer and the catalytical domain with an N-terminal His6-tag and a cleavage site for activation by enterokinase is used
KCAT	Homo sapiens	61	protease-activated receptor-2	*
KCAT	Rattus norvegicus	91	methylsulfonyl-D-cyclohexyltyrosylglycyl-arginine-p-nitroanilide	*construct consisting of the catalytic domain of matriptase fused to Myc-epitope-hexahistidine tag at its carboxyl-terminus treated with recombinant enterokinase
KCAT	Rattus norvegicus	103	methylsulfonyl-D-cyclohexyltyrosylglycyl-arginine-p-nitroanilide	*construct consisting of the catalytic domain of matriptase fused to Myc-epitope-hexahistidine tag at its carboxyl-terminus treated with recombinant enterokinase and glycopeptidase F
KCAT	Homo sapiens	7700	Ile-Pro-Arg-p-nitroanilide	*mutant N164Q/R614A, 37&deg;C, pH 7.4
KCAT	Homo sapiens	390000	Ile-Pro-Arg-p-nitroanilide	*wild-type, pH 7.4, 37&deg;C
KM	Rattus norvegicus	0.164	methylsulfonyl-D-cyclohexyltyrosylglycyl-arginine-p-nitroanilide	*construct consisting of the catalytic domain of matriptase bearing a N772Q mutation fused to Myc-epitope-hexahistidine tag at its carboxyl-terminus treated with recombinant enterokinase
KM	Rattus norvegicus	0.188	methylsulfonyl-D-cyclohexyltyrosylglycyl-arginine-p-nitroanilide	*construct consisting of the catalytic domain of matriptase fused to Myc-epitope-hexahistidine tag at its carboxyl-terminus treated with recombinant enterokinase
KM	Rattus norvegicus	0.2	methylsulfonyl-D-cyclohexyltyrosylglycyl-arginine-p-nitroanilide	*full-length rat matriptase with Myc-epitope-hexahistidine tag at its carboxyl-terminus
KM	Rattus norvegicus	0.228	methylsulfonyl-D-cyclohexyltyrosylglycyl-arginine-p-nitroanilide	*construct consisting of the catalytic domain of matriptase fused to Myc-epitope-hexahistidine tag at its carboxyl-terminus treated with recombinant enterokinase and glycopeptidase F
KM	Homo sapiens	0.104	RQARVVGG	*
KM	Homo sapiens	0.126	RQARVVGG	*
KM	Homo sapiens	0.0033	RRARVVGG	*
KM	Homo sapiens	0.012	RRARVVGG	*
KM	Homo sapiens	0.018	RQARAVGG	*
KM	Homo sapiens	0.128	RQARAVGG	*
KM	Rattus norvegicus	0.582	t-butyloxycarbonyl-L-Gln-L-Ala-L-Arg-4-methyl-coumaryl-7-amide	*catalytic domain, Asp603 - Val855, after treatment with enteropeptidase
KM	Rattus norvegicus	0.59	t-butyloxycarbonyl-L-Gln-L-Ala-L-Arg-4-methyl-coumaryl-7-amide	*extracellular domains, Tyr81 - Val855, after treatment with enteropeptidase
KM	Rattus norvegicus	0.17	methylsulfonyl-D-cyclohexyltyrosyl-glycyl-arginine-p-nitroanilide	*pseudozymogen His6t-S-CD consisting of a spacer and the catalytical domain with an N-terminal His6-tag and a cleavage site for activation by enterokinase is used
KM	Rattus norvegicus	0.19	methylsulfonyl-D-cyclohexyltyrosyl-glycyl-arginine-p-nitroanilide	*engineered L-matriptase (secreted variant of matriptase activated by recombinant enterokinase)
KM	Homo sapiens	0.159	butyloxycarbonyl-L-Gln-L-Ala-L-Arg-4-nitroanilide	*purified matriptase-2, in Tris saline buffer (50 mM Tris, 150 mM NaCl, pH 8.0) at 37&Acirc;&deg;C
KM	Homo sapiens	0.21	butyloxycarbonyl-L-Gln-L-Ala-L-Arg-4-nitroanilide	*matriptase-2 in conditioned medium of HEK-MT2 cells, in Tris saline buffer (50 mM Tris, 150 mM NaCl, pH 8.0) at 37&Acirc;&deg;C
KM	Homo sapiens	0.381	butyloxycarbonyl-L-Gln-L-Ala-L-Arg-4-nitroanilide	*recombinant human matriptase, in Tris saline buffer (50 mM Tris, 150 mM NaCl, pH 8.0) at 37&Acirc;&deg;C
KM	Homo sapiens	0.00381	N-tert-butoxycarbonyl-gamma-benzyl-Glu-Ala-Arg-7-amido-4-methylcoumarin	*pH 8.5
KM	Homo sapiens	0.00489	N-tert-butoxycarbonyl-Gln-Ala-Arg 7-amido-4-methylcoumarin	*pH 8.5
KM	Homo sapiens	0.0335	N-tert-butoxycarbonyl-Gln-Ala-Arg 7-amido-4-methylcoumarin	*pH 8.5
KM	Homo sapiens	0.0699	N-succinyl-Ala-Phe-Lys-7-amido-4-methylcoumarin	*pH 8.5
KM	Homo sapiens	0.159	RAARVVGG	*
KM	Homo sapiens	0.088	RLARVVGG	*
KM	Homo sapiens	0.137	RYARVVGG	*
KM	Homo sapiens	0.124	RQLRVVGG	*
KM	Homo sapiens	0.05	RQRRVVGG	*
KM	Homo sapiens	0.05	RQYRVVGG	*
KM	Homo sapiens	0.065	RQARQVGG	*
KM	Homo sapiens	0.869	RQARYVGG	*
KM	Homo sapiens	0.0136	N-tert-butoxycarbonyl-Leu-Gly-Arg 7-amido-4-methylcoumarin	*pH 8.5
KM	Homo sapiens	0.0475	N-tert-butoxycarbonyl-gamma-benzyl-Glu-Gly-Arg-7-amido-4-methylcoumarin	*pH 8.5
KM	Mus musculus	240	Suc-Ala-Ala-Pro-Arg-p-nitroanilide	*
KM	Mus musculus	534	Suc-Ala-Ala-Pro-Lys-p-nitroanilide	*
KM	Homo sapiens	0.256	Ile-Pro-Arg-p-nitroanilide	*mutant N164Q/R614A, 37&Acirc;&deg;C, pH 7.4
KM	Homo sapiens	0.387	Ile-Pro-Arg-p-nitroanilide	*wild-type, pH 7.4, 37&Acirc;&deg;C
KM	Homo sapiens	0.024	Boc-Gln-Ala-Arg-4-nitroanilide	*pH and temperature not specified in the publication, recombinant c-Myc-tagged mutant H665F
KM	Homo sapiens	0.19	Boc-Gln-Ala-Arg-4-nitroanilide	*pH and temperature not specified in the publication, recombinant c-Myc-tagged mutant A757S
KM	Homo sapiens	0.21	Boc-Gln-Ala-Arg-4-nitroanilide	*pH and temperature not specified in the publication, recombinant c-Myc-tagged wild-type enzyme
KM	Homo sapiens	0.38	Boc-Gln-Ala-Arg-4-nitroanilide	*pH and temperature not specified in the publication, recombinant c-Myc-tagged mutant
KM	Homo sapiens	0.62	Boc-Gln-Ala-Arg-4-nitroanilide	*pH and temperature not specified in the publication, recombinant c-Myc-tagged mutant L785S
KM	Homo sapiens	0.83	Boc-Gln-Ala-Arg-4-nitroanilide	*pH and temperature not specified in the publication, recombinant c-Myc-tagged mutant A757S/L785S
KM	Homo sapiens	1	Boc-Gln-Ala-Arg-4-nitroanilide	*above, pH and temperature not specified in the publication, recombinant c-Myc-tagged mutant E712Y; above, pH and temperature not specified in the publication, recombinant c-Myc-tagged mutant E712Y/A757S/L785S
KM	Homo sapiens	8.35	ABZ-Ile-Arg-Ala-Arg-Ser-Ala-Gly-Tyr(3-NO2)-NH2	*pH and temperature not specified in the publication
KM	Homo sapiens	35.5	ABZ-Ile-Arg-Ala-Arg-Ser-Ala-Ala-Tyr(3-NO2)-NH2	*pH and temperature not specified in the publication
KM	Homo sapiens	24.5	ABZ-Ile-Arg-Ala-Arg-Ser-Ala-Ser-Tyr(3-NO2)-NH2	*pH and temperature not specified in the publication
KM	Homo sapiens	-999	more	*steady-state kinetics
KM	Homo sapiens	-999	more	*pre-steady-state and steady-state kinetics, stopped-flow, overview
KM	Homo sapiens	0.0017	pro-urokinase plasminogen activator	*
KM	Rattus norvegicus	0.00352	single-chain urokinase-type plasminogen activator	*extracellular domains, Tyr81 - Val855, after treatment with enteropeptidase
KM	Rattus norvegicus	0.00599	single-chain urokinase-type plasminogen activator	*catalytic domain, Asp603 - Val855, after treatment with enteropeptidase
KM	Homo sapiens	0.03	filaggrin	*
KM	Homo sapiens	0.046	filaggrin	*
KM	Homo sapiens	0.052	trask	*
KM	Homo sapiens	0.07	trask	*
KM	Homo sapiens	0.1	alphaEbeta7 i tegrin	*
KM	Homo sapiens	0.104	matriptase	*
KM	Homo sapiens	0.111	alphaEbeta7 i tegrin	*
KM	Homo sapiens	0.126	matriptase	*
KM	Homo sapiens	0.142	protease-activated receptor-2	*
KM	Homo sapiens	0.197	protease-activated receptor-2	*
MW	Homo sapiens	110	*	*Western blot analysis using seminal fluid, seminal fluid contains only activated matriptase in complex with antithrombin III, supposed 70 kDa active matriptase and a 40 kDa antithrombin III-fragment
MW	Homo sapiens	25000	*	*serine protease domain, identified by SDS-PAGE, Western blot analysis and LC-MS,MS, without serpin complex
MW	Homo sapiens	26000	*	*determined by SDS-PAGE
MW	Rattus norvegicus	28000	*	*catalytic domain, Asp603 - Val855, after treatment with enteropeptidase, determined by SDS-PAGE and Western blot analysis; extracellular domains, Tyr81 - Val855, after treatment with enteropeptidase, determined by SDS-PAGE and Western blot analysis
MW	Rattus norvegicus	28000	*	*Western blot analysis using conditioned medium, catalytic domain of proteolytically active two-chain matriptase C-terminal fragment
MW	Rattus norvegicus	28000	*	*SDS-PAGE under reducing conditions followed by Western blotting using an anti-matriptase catalytic domain antibody, activated C-terminal part consiting of the catalytic domain; SDS-PAGE under reducing conditions followed by Western blotting using an anti-matriptase catalytic domain antibody, activated form of matriptase
MW	Rattus norvegicus	28000	*	*SDS-PAGE and Western blot analysis, reducing conditions, activated matriptase, disulfide-linked two-chain C-terminal fragment
MW	Homo sapiens	29000	*	*refolded zymogen
MW	Homo sapiens	29000	*	*amino acids 596-855, theoretical molecular mass
MW	Rattus norvegicus	30000	*	*catalytic domain, Asp603 - Val855, before treatment with enteropeptidase, determined by SDS-PAGE and Western blot analysis
MW	Homo sapiens	30000	*	*serine protease domain, determined by SDS-PAGE and Western blot analysis
MW	Rattus norvegicus	30000	*	*SDS-PAGE reducing conditions and Western blot using anti-rat matriptase catalytic domain anibody, designated pseudozymogen His6t-S-CD consisting of a spacer and the catalytical domain with an N-terminal His6-tag and a cleavage site for activation by enterokinase, after cleavage with enterokinase
MW	Homo sapiens	30000	*	*x * 30000, catalytic domain of matriptase-2, SDS-PAGE
MW	Homo sapiens	30000	*	*x * 70000, matriptase zymogen, SDS-PAGE, x * 30000, matriptase serine protease domain, SDS-PAGE
MW	Rattus norvegicus	32000	*	*SDS-PAGE reducing and non-reducing conditions and Western blot using anti-rat matriptase catalytic domain anibody, designated pseudozymogen His6t-S-CD consisting of a spacer and the catalytical domain with an N-terminal His6-tag and a cleavage site for activation by enterokinase, before cleavage with enterokinase
MW	Rattus norvegicus	33000	*	*SDS-PAGE, reducing condition, protease inhibitor cocktail, Western blotting using an anti-myc antibody in a sample of medium, two bands 93 kDa and 33 kDa are visible, 33 kDa fragment is a cleavage product of the carboxyl-terminal part
MW	Rattus norvegicus	33000	*	*SDS-PAGE and Western blot, reducing conditions, proteolytically active, disulfide two-chain matriptase C-terminal fragment found in both the apical and basolateral media of stably transfected Madin-Darby canine kidney cells
MW	Rattus norvegicus	35000	*	*catalytic domain, Asp603 - Val855, before treatment with enteropeptidase, determined by SDS-PAGE and Western blot analysis
MW	Rattus norvegicus	40000	*	*catalytic domain, Asp603 - Val855, before treatment with enteropeptidase, determined by SDS-PAGE and Western blot analysis
MW	Rattus norvegicus	43000	*	*under non-reducing conditions in a sample of medium three bands 61 kDa, 55 kDa, 43 kDa are visible using Western blotting with a anti-myc antibody
MW	Homo sapiens	45000	*	*noncatalytic domain, identified by SDS-PAGE, Western blot analysis and LC-MS,MS
MW	Rattus norvegicus	55000	*	*under non-reducing conditions in a sample of medium three bands 61 kDa, 55 kDa, 43 kDa are visible using Western blotting with a anti-myc antibody
MW	Homo sapiens	60000	*	*serine protease domain, dimer, determined by SDS-PAGE and Western blot analysis
MW	Rattus norvegicus	61000	*	*under non-reducing conditions in a sample of medium three bands 61 kDa, 55 kDa, 43 kDa are visible using Western blotting with a anti-myc antibody
MW	Homo sapiens	70000	*	*1 * 70000 + 1 * 240000, complex purified from milk, SDS-PAGE
MW	Homo sapiens	70000	*	*SDS-PAGE
MW	Homo sapiens	70000	*	*non-complexed form, SDS-PAGE
MW	Homo sapiens	70000	*	*immunoblotting, latent NH2 terminal processed form matripase
MW	Homo sapiens	70000	*	*x * 70000, inactive zymogen, SDS-PAGE
MW	Homo sapiens	70000	*	*SDS-PAGE, reducing condition, and Western blot, latent form of matriptase
MW	Homo sapiens	70000	*	*x * 70000, SDS-PAGE
MW	Homo sapiens	70000	*	*x * 70000, SDS-PAGE; x * 70000, SDS-PAGE
MW	Homo sapiens	70000	*	*x * 70000, matriptase zymogen, SDS-PAGE, x * 30000, matriptase serine protease domain, SDS-PAGE
MW	Homo sapiens	75000	*	*calculated from nucleic acid sequence
MW	Homo sapiens	75000	*	*gelatin zymography, soluble active enzyme
MW	Homo sapiens	75000	*	*by immunoblotting or zymography
MW	Homo sapiens	75000	*	*x * 75000, native enzyme, SDS-PAGE
MW	Homo sapiens	80000	*	*noncomplexed form purified from T47D cells, SDS-PAGE
MW	Homo sapiens	80000	*	*SDS-PAGE, recombinant protease domain
MW	Homo sapiens	80000	*	*immunoblotting, membrane-bound enzyme
MW	Homo sapiens	80000	*	*x * 95000, full-length transmembrane isoform, SDS-PAGE, x * 80000, Gly149-early processed isoform, SDS-PAGE, x * 26000-29000, activated recombinant truncated wild-type catalytic domain, SDS-PAGE
MW	Homo sapiens	80000	*	*serine protease domain, identified by SDS-PAGE, Western blot analysis and LC-MS,MS, including serpin complex
MW	Homo sapiens	84000	*	*calculated molecular mass
MW	Homo sapiens	85000	*	*and 95000 Da, SDS-PAGE, complex derived from milk
MW	Homo sapiens	85000	*	*SDS-PAGE, full length enzyme
MW	Homo sapiens	85000	*	*immunoblotting, full-length hepatocyte growth factor activator inhibitor-1 complexed with the serine protease domain of matripase
MW	Homo sapiens	85000	*	*Western blot analysis using seminal fluid, seminal fluid contains only activated matriptase in complex with hepatocyte growth factor activator inhibitor-1 (HAI-1), supposed 70 kDa active matriptase and a 15 kDa HAI-fragment
MW	Homo sapiens	85000	*	*SDS-PAGE and Western blot, reducing conditions, cleaved form of the enzyme
MW	Homo sapiens	88900	*	*
MW	Mus musculus	90000	*	*x * 90000, SDS-PAGE
MW	Rattus norvegicus	90000	*	*Western blot analysis, post-translational processed enzyme, cleavage between Gly149 and Ser150 within the SEA domain
MW	Rattus norvegicus	90000	*	*Western blot analysis using conditioned medium, proteolytically inactive single-chain C-terminal fragment
MW	Rattus norvegicus	90000	*	*SDS-PAGE under reducing conditions followed by Western blotting using an anti-matriptase catalytic domain antibody, non-activated C-terminal part; SDS-PAGE under reducing conditions followed by Western blotting using an anti-matriptase catalytic domain antibody, non-activated form of matriptase
MW	Rattus norvegicus	90000	*	*SDS-PAGE and Western blot analysis, reducing conditions, non-activated enzyme, single-chain C-terminal fragment
MW	Homo sapiens	93000	*	*immunoblotting, latent full-length matripase
MW	Rattus norvegicus	93000	*	*SDS-PAGE, reducing condition, protease inhibitor cocktail, Western blotting using an anti-myc antibody in a sample of medium, two bands 93 kDa and 33 kDa are visible. 93 kDa fragment represents released single-chain carboxyl-terminal part
MW	Rattus norvegicus	93000	*	*SDS-PAGE and Western blot, reducing conditions, proteolytically inactive, single-chain matriptase C-terminal fragment found in both the apical and basolateral media of stably transfected Madin-Darby canine kidney cells
MW	Homo sapiens	95000	*	*complexed with HAI-1, purified from milk, SDS-PAGE
MW	Homo sapiens	95000	*	*complex can be converted by boiling to matriptase plus a 40000 Da protein doublet
MW	Homo sapiens	95000	*	*and 85000 Da, SDS-PAGE, complex derived from milk
MW	Homo sapiens	95000	*	*gelatin zymography or immunoblotting, matripase/hepatocyte growth factor activator inhibitor complex
MW	Homo sapiens	95000	*	*x * 95000, single-chain latent enzyme, SDS-PAGE, x * 120000, active enzyme in complex with inhibitor HAI-1, SDS-PAGE
MW	Homo sapiens	95000	*	*x * 95000, full-length transmembrane isoform, SDS-PAGE, x * 80000, Gly149-early processed isoform, SDS-PAGE, x * 26000-29000, activated recombinant truncated wild-type catalytic domain, SDS-PAGE
MW	Rattus norvegicus	95000	*	*extracellular domains, Tyr81 - Val855, before treatment with enteropeptidase, determined by SDS-PAGE and Western blot analysis
MW	Homo sapiens	95000	*	*Western blot analysis using seminal fluid or urine, seminal fluid or urine contain only activated matriptase in complex with hepatocyte growth factor activator inhibitor-1 (HAI-1), supposed 70 kDa active matriptase and a 25 kDa HAI-fragment
MW	Homo sapiens	95000	*	*Western blot analysis, reducing conditions
MW	Homo sapiens	100000	*	*immunoblotting, matripase-hepatocyte growth factor activator inhibitor-1 complex
MW	Rattus norvegicus	110000	*	*Western blot analysis, unprocessed enzyme
MW	Homo sapiens	110000	*	*gelatin zymography or immunoblotting, matripase/hepatocyte growth factor activator inhibitor complex
MW	Homo sapiens	110000	*	*matripase complex
MW	Homo sapiens	120000	*	*complexed form, SDS-PAGE
MW	Homo sapiens	120000	*	*immunoblotting, 70000 active matripase plus full-length hepatocyte growth factor activator inhibitor-1
MW	Homo sapiens	120000	*	*x * 95000, single-chain latent enzyme, SDS-PAGE, x * 120000, active enzyme in complex with inhibitor HAI-1, SDS-PAGE
MW	Homo sapiens	120000	*	*SDS-PAGE, reducing condition, and Western blot, activated form of matriptase in complex with hepatocyte growth factor activator inhibitor 1
MW	Homo sapiens	130000	*	*SDS-PAGE and Western blot, reducing conditions, matriptase-hepatcyte growth factor activator inhibitor-1 complex
MW	Homo sapiens	240000	*	*1 * 70000 + 1 * 240000, complex purified from milk, SDS-PAGE
SA	Homo sapiens	-999	*	*quantitative expression analysis of matriptase-1 in breast cancer samples, overview; quantitative expression analysis of matriptase-2 in breast cancer samples, overview
SA	Homo sapiens	-999	*	*
